CP-LC-0729
Version 1.5c45e63d · 2026-09-13
| CAS No. | Not available |
| Chemical Name | CP-LC-0729 |
| Synonyms | CPLC0729， CP LC 0729 |
| SMILES | O=C(C(NC(C(CCCCCCCC)CCCCCC)=O)CCSCCC(OCC(CCCCCCCC)CCCCCC)=O)NCCN(C)C |
| Formula | C43H85N3O4S |
| M.Wt | 740.2 |
| Purity | Not available |
| Storage | Original product: up to 1 year under the storage conditions stated on the vial, kept tightly sealed. Stock solutions: aliquots at -20°C, generally up to one month. |
| Shipping condition | Ships from Shanghai. Pure lipid is stable during ice-pack transport. |
| Publication | Not available |
Lipid CP-LC-0729, an ionizable cationic amino lipid synthesized from homocysteine—a naturally occurring amino acid—has been shown to exhibit superior efficacy in the delivery and subsequent protein expression of various RNA modalities, including messenger RNA (mRNA), circular RNA (cRNA), and self-amplifying RNA (saRNA) in vivo. Importantly, CP-LC-0729 demonstrates an exemplary safety profile, with no observable toxicological effects in preclinical studies. Comparative analyses reveal that CP-LC-0729 significantly surpasses MC3, a widely utilized benchmark lipid nanoparticle formulation, in terms of protein expression efficiency. Specifically, CP-LC-0729 achieves a striking 32-fold enhancement in protein expression within lung tissue relative to MC3, underscoring its pronounced tissue selectivity and targeting efficacy for pulmonary applications. These findings suggest that CP-LC-0729 represents a highly promising candidate for the development of RNA-based therapeutics, particularly in the context of lung-targeted delivery systems, where its combination of high efficiency and low toxicity offers significant translational potential.
Specifications shown are product-page values, not batch test results.
Read Instructions for Use →